Biography
Dr Shalini Subramaniam delivers compassionate, patient-centred cancer care. She values open and honest conversations and works closely with patients and their loved ones to support informed decision-making at every stage of treatment.
Dr Shalini Subramaniam is a medical oncologist at Icon Cancer Centre Revesby. She completed a Bachelor of Medicine and Bachelor of Surgery (MBBS) at the University of New South Wales in 2011 and is a Fellow of the Royal Australasian College of Physicians (FRACP). She also holds a Master of Medicine in Clinical Epidemiology and a Doctor of Philosophy from the University of Sydney.
Dr Subramaniam has extensive experience in the management of breast, lung and genitourinary cancers and is actively involved in clinical trials, including investigator-initiated and cooperative group studies. She has authored multiple peer-reviewed publications in leading international journals, including The Lancet and The Lancet Oncology, and regularly presents at national and international scientific meetings. She is also a Research Fellow at the NHMRC Clinical Trials Centre, where she provides clinical input supporting the development and conduct of genitourinary and lung cancer trials.
A key focus of Dr Subramaniam’s work is understanding how treatment benefits and outcomes are communicated and understood in advanced cancer. This informs her clinical approach, supporting clear, evidence-based discussions and shared decision-making tailored to each patient’s goals and priorities. She works closely with multidisciplinary teams to deliver high quality, evidence-based cancer care.
Her clinical experience covers a broad range of solid tumour malignancies, with a special interest in breast cancer, genitourinary cancers and lung cancer.
Publications
Emmett L, Subramaniam S, Crumbaker M, et al. Overall survival and quality of life with ¹⁷⁷Lu‑PSMA‑617 plus enzalutamide versus enzalutamide alone in metastatic castration‑resistant prostate cancer (ENZA‑p). The Lancet Oncology. 2025;26(3):291–299. doi:10.1016/S1470‑2045(25)00009‑9
Subramaniam S, Bui K, Stockler M, Kiely B. Curability of metastatic cancer: a survey of medical oncologists, JNCI Cancer Spectrum, Volume 10, Issue 1, February 2026, pkaf115, https://doi.org/10.1093/jncics/pkaf115
Emmett L, Subramaniam S, Crumbaker M, et al. ¹⁷⁷Lu‑PSMA‑617 plus enzalutamide in patients with metastatic castration‑resistant prostate cancer (ENZA‑p): an open‑label, multicentre, randomised, phase II trial. The Lancet Oncology. 2024;25(5):563–571. doi:10.1016/S1470‑2045(24)00135‑9
Lee CK, Liao BC, Subramaniam S, et al. Durvalumab, tremelimumab, and platinum chemotherapy in EGFR mutation‑positive non‑small cell lung cancer (ILLUMINATE). JTO Clinical and Research Reports. 2024;6(2):100771. Published November 2024. doi:10.1016/j.jtocrr.2024.100771
Subramaniam S, Adams DH, Tognela A, et al. Patients’ perception of the benefits of palliative systemic therapy for advanced cancer. Internal Medicine Journal. 2024;54(5):735–741. doi:10.1111/imj.16325